Abstract
Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastasis. Experimental and clinical data demonstrated that breast cancer is an angiogenesis-dependent disease and that the vascular endothelial growth factor (VEGF) family plays a key role it being a highly expressed and selective endothelial cell growth factor. Preclinical studies have shown that the angiogenic switch occurs early in the multistage process of breast cancer development. Targeting the molecular pathways involved in tumor progression by biologically-designed treatments is a new therapeutic paradigm aimed to reach cancer growth control. A number of possible therapeutic targets for antiangiogenic agents have been identified. Here we discuss the therapeutic approach based on inhibition of angiogenesis in the context of breast cancer with a focus on the early clinical studies on antiangiogenic agents in advanced disease.
| Original language | English |
|---|---|
| Pages (from-to) | 91-107 |
| Number of pages | 17 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 49 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2004 |
Fingerprint
Keywords
- Angiogenesis
- Antiangiogenic therapy
- Breast cancer
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Antiangiogenic strategies, compounds, and early clinical results in breast cancer. / Morabito, Alessandro; Sarmiento, Roberta; Bonginelli, Paola; Gasparini, Giampietro.
In: Critical Reviews in Oncology/Hematology, Vol. 49, No. 2, 02.2004, p. 91-107.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiangiogenic strategies, compounds, and early clinical results in breast cancer
AU - Morabito, Alessandro
AU - Sarmiento, Roberta
AU - Bonginelli, Paola
AU - Gasparini, Giampietro
PY - 2004/2
Y1 - 2004/2
N2 - Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastasis. Experimental and clinical data demonstrated that breast cancer is an angiogenesis-dependent disease and that the vascular endothelial growth factor (VEGF) family plays a key role it being a highly expressed and selective endothelial cell growth factor. Preclinical studies have shown that the angiogenic switch occurs early in the multistage process of breast cancer development. Targeting the molecular pathways involved in tumor progression by biologically-designed treatments is a new therapeutic paradigm aimed to reach cancer growth control. A number of possible therapeutic targets for antiangiogenic agents have been identified. Here we discuss the therapeutic approach based on inhibition of angiogenesis in the context of breast cancer with a focus on the early clinical studies on antiangiogenic agents in advanced disease.
AB - Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastasis. Experimental and clinical data demonstrated that breast cancer is an angiogenesis-dependent disease and that the vascular endothelial growth factor (VEGF) family plays a key role it being a highly expressed and selective endothelial cell growth factor. Preclinical studies have shown that the angiogenic switch occurs early in the multistage process of breast cancer development. Targeting the molecular pathways involved in tumor progression by biologically-designed treatments is a new therapeutic paradigm aimed to reach cancer growth control. A number of possible therapeutic targets for antiangiogenic agents have been identified. Here we discuss the therapeutic approach based on inhibition of angiogenesis in the context of breast cancer with a focus on the early clinical studies on antiangiogenic agents in advanced disease.
KW - Angiogenesis
KW - Antiangiogenic therapy
KW - Breast cancer
UR - http://www.scopus.com/inward/record.url?scp=0842328584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0842328584&partnerID=8YFLogxK
U2 - 10.1016/S1040-8428(03)00168-9
DO - 10.1016/S1040-8428(03)00168-9
M3 - Article
C2 - 15012971
AN - SCOPUS:0842328584
VL - 49
SP - 91
EP - 107
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 2
ER -